Cargando…

Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis

Background: Acquired dysfunctional immunity in cirrhosis predisposes patients to frequent bacterial infections, especially spontaneous bacterial peritonitis (SBP), leading to systemic inflammation that is associated with poor outcome. But systemic inflammation can also be found in the absence of a c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alvarez-Silva, Camila, Schierwagen, Robert, Pohlmann, Alessandra, Magdaleno, Fernando, Uschner, Frank E., Ryan, Patrick, Vehreschild, Maria J. G. T., Claria, Joan, Latz, Eicke, Lelouvier, Benjamin, Arumugam, Manimozhiyan, Trebicka, Jonel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376951/ https://www.ncbi.nlm.nih.gov/pubmed/30800122 http://dx.doi.org/10.3389/fimmu.2019.00069

Ejemplares similares

Trust is good, control is better: technical considerations in blood microbiome analysis
por: Schierwagen, Robert, et al.
Publicado: (2020)

Hepatic inflammasome activation as origin of Interleukin-1α and Interleukin-1β in liver cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2021)

Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS
por: Queck, Alexander, et al.
Publicado: (2020)

Albumin in decompensated cirrhosis: new concepts and perspectives
por: Bernardi, Mauro, et al.
Publicado: (2020)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2018)

Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis
por: Queck, Alexander, et al.
Publicado: (2019)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis
por: Torres, Sandra, et al.
Publicado: (2021)

Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation
por: Stoffers, Philipp, et al.
Publicado: (2022)

Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease
por: Tyc, Olaf, et al.
Publicado: (2020)

Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis
por: Klein, Sabine, et al.
Publicado: (2015)

Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation
por: Casey, Stephen, et al.
Publicado: (2019)

Impact of Bacterial Translocation on Sarcopenia in Patients with Decompensated Cirrhosis
por: Tsien, Cynthia, et al.
Publicado: (2019)

Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt
por: Praktiknjo, Michael, et al.
Publicado: (2019)

Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis
por: Trebicka, Jonel, et al.
Publicado: (2019)

Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats
por: Klein, Sabine, et al.
Publicado: (2019)

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
por: Pose, Elisa, et al.
Publicado: (2021)

A New Treatment for Chronic Hepatitis B and D Offers Novel Insights Into Obesity and Hepatic Steatosis
por: Schierwagen, Robert, et al.
Publicado: (2020)

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
por: Iwakiri, Yasuko, et al.
Publicado: (2021)

Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis
por: Queck, Alexander, et al.
Publicado: (2020)

Future therapy of portal hypertension in liver cirrhosis – a guess
por: Sauerbruch, Tilman, et al.
Publicado: (2014)

Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough
por: Laleman, Wim, et al.
Publicado: (2018)

The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension
por: Uschner, Frank Erhard, et al.
Publicado: (2018)

Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
por: Weiss, Emmanuel, et al.
Publicado: (2023)

Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension
por: Klein, Sabine, et al.
Publicado: (2016)

β-Arrestin2 is increased in liver fibrosis in humans and rodents
por: Schierwagen, Robert, et al.
Publicado: (2020)

Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis
por: Wirtz, Theresa H., et al.
Publicado: (2020)

The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease
por: Schierwagen, Robert, et al.
Publicado: (2020)

Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction
por: Sauerbruch, Tilman, et al.
Publicado: (2021)

Portal vein thrombosis in patients with cirrhosis
por: von Köckritz, Leona, et al.
Publicado: (2017)

Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments
por: Herath, Chandana B., et al.
Publicado: (2022)

Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis
por: Benz, Fabian, et al.
Publicado: (2020)

Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF
por: Weiss, Emmanuel, et al.
Publicado: (2021)

Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure
por: Nielsen, Marlene Christina, et al.
Publicado: (2020)

TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor
por: Klein, Sabine, et al.
Publicado: (2019)

Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure
por: Blaya, Delia, et al.
Publicado: (2021)

Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial
por: Kronborg, Thit M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_567upqm9m4bfm7hsslk3bb8nvl